Patient has alopecia totalis, alopecia universalis, or alopecia areata with ophiasis pattern.

Known allergy or hypersensitivity to triamcinolone acetonide

Pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4 weeks after the study.

Patient is unable/unwilling to provide informed assent when applicable.

Known medical diagnosis or use of a medication that alters pain response at time of injection.

Active infection at site designated for injection.

If currently being treated for alopecia areata, the current treatment regimen has been started within less than 4 weeks of screening.

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata